Detalhe da pesquisa
1.
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies.
Blood;
2024 May 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38781564
2.
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.
Blood;
139(15): 2306-2315, 2022 04 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35167655
3.
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.
Blood Adv;
7(5): 768-777, 2023 03 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35468618
4.
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
J Immunother Cancer;
10(1)2022 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34996813